Agenus Inc (AGEN)

$2.85 -0.02 (-0.70%)
Market Cap 72.64M
Revenue (ttm) 103.46M
Net Income (ttm) -227.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -219.61%
Debt to Equity Ratio -0.11
Volume 1,573,100
Avg Vol 543,372
Day's Range N/A - N/A
Shares Out 25.31M
Stochastic %K 70%
Beta 1.58
Analysts Sell
Price Target $7.00

Latest News on AGEN

Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025

Apr 23, 2025, 12:05 PM EDT - 16 hours ago

Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025

Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025

Mar 25, 2025, 4:40 PM EDT - 4 weeks ago

Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025

Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation

Mar 19, 2025, 7:30 AM EDT - 5 weeks ago

Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation

Agenus Inc. (AGEN) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 10:39 AM EDT - 6 weeks ago

Agenus Inc. (AGEN) Q4 2024 Earnings Call Transcript

Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program

Mar 11, 2025, 7:30 AM EDT - 6 weeks ago

Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program

Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications

Feb 26, 2025, 4:48 PM EST - 2 months ago

Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications

Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference

Feb 25, 2025, 2:30 PM EST - 2 months ago

Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference

Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

Feb 25, 2025, 8:26 AM EST - 2 months ago

Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting

Feb 24, 2025, 8:33 AM EST - 2 months ago

Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting

CORRECTING and REPLACING Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

Feb 23, 2025, 7:38 PM EST - 2 months ago

CORRECTING and REPLACING Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

Feb 12, 2025, 1:00 PM EST - 2 months ago

Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Jan 29, 2025, 12:37 PM EST - 3 months ago

Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease

Jan 22, 2025, 2:48 PM EST - 3 months ago

Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease

Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers

Dec 18, 2024, 7:30 AM EST - 4 months ago

Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers

Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs

Dec 5, 2024, 7:30 AM EST - 4 months ago

Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs

Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment

Nov 27, 2024, 8:15 AM EST - 5 months ago

Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment

Agenus Inc. (AGEN) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 10:41 AM EST - 5 months ago

Agenus Inc. (AGEN) Q3 2024 Earnings Call Transcript

Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development

Nov 12, 2024, 7:00 AM EST - 5 months ago

Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development

Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024

Nov 7, 2024, 10:00 AM EST - 5 months ago

Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024

Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update

Nov 5, 2024, 7:30 AM EST - 6 months ago

Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update

November 5 Deadline: Agenus Inc Is Being Sued For Defrauding The Public And Affected Shareholders Are Urged To Contact The Schall Law Firm

Nov 4, 2024, 11:00 AM EST - 6 months ago

November 5 Deadline: Agenus Inc Is Being Sued For Defrauding The Public And Affected Shareholders Are Urged To Contact The Schall Law Firm

Agenus Inc Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Urged To Contact The Schall Law Firm

Nov 2, 2024, 11:00 AM EDT - 6 months ago

Agenus Inc Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Urged To Contact The Schall Law Firm

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus

Oct 30, 2024, 6:30 PM EDT - 6 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus

Agenus Inc Is Being Sued For Violating Securities Laws And Impacted Shareholders Are Urged To Reach Out To The Schall Law Firm

Oct 24, 2024, 11:00 AM EDT - 6 months ago

Agenus Inc Is Being Sued For Violating Securities Laws And Impacted Shareholders Are Urged To Reach Out To The Schall Law Firm

Agenus Inc Is Being Sued For Violating Securities Laws And Impacted Shareholders Are Urged To Contact The Schall Law Firm

Oct 20, 2024, 11:00 AM EDT - 6 months ago

Agenus Inc Is Being Sued For Violating Securities Laws And Impacted Shareholders Are Urged To Contact The Schall Law Firm

Agenus Inc Is Being Sued For Violating Securities Laws And Affected Shareholders Are Urged To Reach Out To The Schall Law Firm

Oct 18, 2024, 11:00 AM EDT - 6 months ago

Agenus Inc Is Being Sued For Violating Securities Laws And Affected Shareholders Are Urged To Reach Out To The Schall Law Firm

The Schall Law Firm Encourages Investor Participation In A Case Against Agenus Inc. For Securities Related Infractions

Oct 17, 2024, 11:00 AM EDT - 6 months ago

The Schall Law Firm Encourages Investor Participation In A Case Against Agenus Inc. For Securities Related Infractions

Agenus Inc Is Being Sued For Possible Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm

Oct 16, 2024, 11:00 AM EDT - 6 months ago

Agenus Inc Is Being Sued For Possible Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm

Agenus Inc Is Being Sued For Possible Securities Fraud And Affected Stockholders Are Urged To Reach Out To The Schall Law Firm

Oct 14, 2024, 11:00 AM EDT - 6 months ago

Agenus Inc Is Being Sued For Possible Securities Fraud And Affected Stockholders Are Urged To Reach Out To The Schall Law Firm